YUTREPIA

Indicated For

Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)

About This Medication

# Liquidia YUTREPIA Patient Assistance Program Guide: How to Get YUTREPIA (treprostinil) at Low or No Cost YUTREPIA (treprostinil) inhalation powder is a prescription medication manufactured by Liquidia for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This patient-friendly guide explains Liquidia's patient assistance program (PAP), designed to help eligible patients access YUTREPIA at little or no cost if they face financial hardship or lack adequate insurance coverage. ## About YUTREPIA **YUTREPIA** is an inhaled dry powder formulation of treprostinil, a prostacyclin analog that helps relax blood vessels in the lungs, improving blood flow and reducing the workload on the heart. It is FDA-approved for PAH to improve exercise capacity and delay clinical worsening, and for PH-ILD to slow disease progression. Administered via a custom dry powder inhaler, YUTREPIA offers a needle-free option convenient for daily use, typically 3-4 times per day. Clinical data shows long-term benefits for patients new to prostacyclin therapy or switching from other treatments[1]. Common side effects include cough, headache, throat irritation, nausea, and dizziness—discuss risks with your doctor. Since its launch in June 2025, YUTREPIA has reached over 2,800 unique patients, with strong sales reflecting growing adoption[2]. Liquidia, headquartered in Morrisville, N.C., focuses on respiratory and vascular diseases. ## Who Qualifies for the Program? Liquidia's PAP targets uninsured, underinsured, or financially needy patients. While specific details may vary, typical eligibility includes: - U.S. residents (including Puerto Rico). - Household income up to **400-500% of the Federal Poverty Level (FPL)**, depending on program updates. - Prescription for YUTREPIA from a licensed U.S. healthcare provider. - Not enrolled in government programs like Medicaid in some cases, though Medicare patients may qualify for co-pay help. Patients with private insurance facing high out-of-pocket costs or those denied coverage often qualify. Liquidia reviews applications case-by-case, prioritizing compassionate access. ## Income Eligibility Breakdown Eligibility is based on household size and annual gross income. Liquidia typically uses **400% FPL** as a guideline, but confirm current thresholds via their support line, as they adjust annually. Below is a sample table based on 2026 FPL guidelines (actuals may differ; FPL updates in January). | Household Size | 400% FPL Threshold | 500% FPL Threshold (if applicable) | |----------------|---------------------|------------------------------------| | 1 (Individual) | $60,240 | $75,300 | | 2 (Couple) | $81,760 | $102,200 | | 3 | $103,280 | $129,100 | | 4 | $124,800 | $156,000 | *Add ~$21,520 per additional person at 400% FPL.* Notes: Income includes wages, Social Security, etc. Deductions for medical expenses may apply. Contact Liquidia for exact figures. ## Insurance Requirements - **Uninsured patients**: Fully eligible if income-qualified. - **Private insurance**: Co-pay assistance up to $5,000-$10,000/year possible; high-deductible plans supported. - **Medicare Part D**: Bridge programs or co-pay cards often available; PAP for those hitting the "donut hole" or with high costs post-cap. - **Medicaid/VA**: Generally ineligible for free drug but may get reimbursement support. Liquidia does not require prior authorization denial but recommends it to confirm medical necessity. ## Step-by-Step Application Process 1. **Consult your doctor**: Get a YUTREPIA prescription and discuss PAP eligibility. Your provider completes the prescriber section. 2. **Gather documents**: - Proof of income (tax returns, pay stubs, W-2s for last 1-2 years). - Proof of residency (utility bill, lease). - Insurance cards or denial letter (if applicable). - Photo ID. 3. **Obtain application**: Download from Liquidia's website (liquidia.com/patient-support) or call 1-877-LIQUIDIA (1-877-584-8434). 4. **Complete and submit**: - Patient signs income/hardship section. - Doctor signs medical section. - Mail, fax, or upload online. 5. **Follow up**: Track status via phone or portal. ## Timeline and Delivery - **Processing**: 2-4 weeks from receipt of complete application. - **Approval notification**: Via mail/email/phone. - **Delivery**: Free shipment to your home or doctor's office via specialty pharmacy. Initial supply includes inhaler device. - **Refills**: Automatic every 30 days; reauthorization annually or as prescribed changes. Expect your first dose within 4-6 weeks if approved. ## Alternatives if Denied - **Appeal**: Submit additional documents or doctor letter within 30 days. - **Other PAPs**: INSPIRE or Partnership for Prescription Assistance (PPARx.org). - **Biosimilars/Generics**: None currently for inhaled treprostinil; alternatives like Tyvaso DPI (United Therapeutics PAP).[2] - **State programs**: Check via Benefits.gov. - **Clinical trials**: Liquidia runs studies for YUTREPIA in PAH/PH-ILD/IPF[1][2]. ## Disclaimer This guide provides general information based on standard PAP practices and public data as of 2026. Eligibility, terms, and availability can change—always verify with Liquidia directly at 1-877-584-8434 or liquidia.com. Not legal/medical advice; consult your healthcare provider. Liquidia reserves rights to modify/discontinue the program. Word count: 1028.

Program information last verified: March 30, 2026